Sector News

Sanofi strategy exec Mansuri jumps ship ahead of new CEO’s big reveal

November 25, 2019
Life sciences

New Sanofi CEO Paul Hudson is days away from unveiling his plans for the French drugmaker, but the company’s top strategy executive won’t wait that long to leave.

Muzammil Mansuri, Sanofi’s executive vice president of strategy and business development since February 2016, will retire by the end of the month, a spokeswoman confirmed. Reuters first reported the departure Friday morning.

Mansuri has played a “key role” in Sanofi’s strategic moves over the last four years, overseeing recent acquisitions and “structuring partnerships and alliances that contributed to the deployment of our strategy and growth,” Sanofi’s spokeswoman said. The retirement had been planned, she added.

Sanofi’s recent acquisitions include two wrapped up last year: the hemophilia-focused Bioverativ for $11.6 billion and nanobody biotech Ablynx for $4.8 billion. The moves were designed to reduce the drugmaker’s reliance on diabetes and cardiovascular meds, which have been struggling against pricing pressure and stepped-up competition for several years.

With Mansuri’s departure, Sanofi said Alban de La Sablière, its business development head, and Laurent Van Lerberghe, its strategy head, will take on more responsibilities starting Dec. 1.

The news comes a few months into Hudson’s tenure and ahead of an investor event Dec. 10 in Cambridge, Massachusetts. Since he joined Sanofi from Novartis at the beginning of September, Hudson has been touring Sanofi’s facilities to learn as much about the company as possible.

He’s also been reviewing each of the company’s divisions, and Bloomberg reported this week the drugmaker is considering a sale or spinoff of its consumer healthcare business. The group brings in $5 billion annually.

Mansuri joined Sanofi from Gilead Sciences and had prior experience at Bristol-Myers, CGI Pharmaceuticals and Shell Research Limited.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”